Clinical Perspective: Statins and the Liver - Harmful or Helpful?

Digestive Diseases and Sciences

Volumn 57, Issue 7, 2012, Pages 1754-1763

  Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PEGINTERFERON; PITAVASTATIN; PLACEBO; PRAVASTATIN; RIBAVIRIN; SIMVASTATIN; TROGLITAZONE;

ACUTE LIVER FAILURE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER PROTECTION; LIVER TOXICITY; MORBIDITY; MUSCLE INJURY; NONHUMAN; PATIENT MONITORING; PORTAL HYPERTENSION; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; TOXIC HEPATITIS;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIVER; PREVALENCE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84864280822     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2207-3     Document Type: Review

References (103)

1. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. Accessed at: www.fda.gov/Drugs/DrugSafety/ ucm293101.htm. Posted Feb 28, 2012.
2. FDA Consumer Alert: Statins and HIV or Hepatitis C Drugs: drug safety communication - interaction increases risk of muscle injury. Accessed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm294294.htm, Posted March 1, 2012.
3. FDA Consumer Alert: Important information about interactions between certain hepatitis C drugs and cholesterol-lowering statin drugs. Accessed at: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm294485.htm. Posted March 2, 2012.
4. Rzouq FS, Volk ML, Hatoum HH, et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci. 2010;340:89-93.
5. Bergmann OM, Kristjansson G, Jonasson JG, Bjornsson ES. Jaundice due to suspected statin hepatotoxicity: a case series. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-011-1950-1.
6. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury postmarketing. J Hepatol. 2012;56:374-380.
7. Tolman KG. The liver and lovastatin. Am J Cardiol. 2002; 89:1374-1380. (Pubitemid 34607777)
8. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have a higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci. 2005;329:62-65. (Pubitemid 40250595)
9. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008; 48:662-669.
10. Onusko E. Statins and elevated liver tests: what's the fuss? J Fam Pract. 2008;57:449-452.
11. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010;105:978-980.
12. Bader T. Liver tests are irrelevant when prescribing statins. Lancet. 2010;376:1882-1883.
13. Bader T. Yes! Statins can be given to liver patients. J Hepatol. 2012;56:305-307.
14. Cohen DE, Anania FA, Chalasani N, The National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97:S77-S81.
15. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29: 412-422.
16. Athyros VG, Tziomalos K, Gossios T, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests; in the Greek atorvastatin and coronary heart disease evaluation (GREACE) study: a post hoc analysis. Lancet. 2010;376: 1916-1922.
17. Zamor PJ, Russo MW. Liver function tests and statins. Curr Opin Cardiol. 2011;26:338-341.
18. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453-1563.
19. Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010;85:349-356.
20. Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med. 2009;11:272-278.
21. Tzefos M, Olin JL. 3-hydroxyl-3-methylglutaryl coenzyme a reductase inhibitor use in chronic liver disease: a therapeutic controversy. J Clin Lipidol. 2011;5:450-459.
22. Tolman K. Defining patient risks from expanded preventive therapies. Am J Cardiol. 2000;85:15E-19E.
23. Avins AL, Manos MM, Ackerson L, et al. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study. Drug Saf. 2008;31:325-334. (Pubitemid 351441580)
24. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41:690-695. (Pubitemid 40462927)
25. Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant druginduced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40:1095-1101. (Pubitemid 41291360)
26. Björnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis. 2006;38:33-38. (Pubitemid 44356129)
27. Kornbrust DJ, MacDonald JS, Peter CP, et al. Toxicity of the HMG-CoA reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther. 1989;248:498-505. (Pubitemid 19090215)
28. Horsmans Y, DeSager JP, Harveng TC. Biochemical changes and morphological alterations of the liver in guinea pigs after administration of simvastatin HMG-CoA reductase-inhibitor. Pharmacol Toxicol. 1990;67:336-339. (Pubitemid 20358741)
29. Zimmerman HJ. The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999:662.
30. Tavintharan S, Ong CN, Jeyaseelan K, et al. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepato-toxicity? Toxicol Appl Pharmacol. 2007;223:173-179. (Pubitemid 47348060)
31. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231-2237. (Pubitemid 46856819)
32. Nawarskas JJ. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev. 2005;13:76-79. (Pubitemid 40279875)
33. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788-2797. (Pubitemid 46018281)
34. de Denus S, Spinler SA, Miller K, et al. Statins and liver tox-icity: a meta-analysis. Pharmacotherapy. 2004;24:584-591.
35. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective pravastatin pooling (PPP) project. Circulation. 2002;105:2341-2346. (Pubitemid 34556383)
36. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622. (Pubitemid 28248586)
37. Charles EC, Olson KL, Sandhoff BG, et al. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med. 2005;118:618-624. (Pubitemid 40732701)
38. Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing Database. Liver Transpl. 2009;15:719-729.
39. Reuben A, Koch DG, Lee WM, The Acute Liver Failure Study Group. Drug-induced acute liver failure: results of an US Multicenter, prospective study. Hepatology. 2010;52:2065-2076.
40. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512-521. (Pubitemid 41096639)
41. Björnsson E, Olsson R. Outcome and prognostic markers in sever drug-induced liver disease. Hepatology. 2005;42:481-489. (Pubitemid 41061102)
42. Devarbhavi H, Dierkhising R, Kremers WK, et al. Single center experience with drug-induced liver injury from India: Causes, outcomes, prognosis, and predictors of mortality. Am J Gastroenterol. 2010;105:2396-2404.
43. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of druginduced liver injury in the United States. Gastroenterology. 2008;135:1924-1934.
44. Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo GP, eds. Advances in inflammation research, vol. 6. New York: Raven Press; 1984:1-7.
45. Davern TJ, Chalasani N, Fontana RJ, et al. Acute Hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665-1672.
46. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26:1429-1435. (Pubitemid 350045603)
47. Lewis JH. Drug-induced liver disease. Med Clin North Am. 2000;84:1275-1311.
48. Lewis JH. Liver disease caused by anesthetics, toxins, and herbal preparations. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Diseases. Pathophysiology/Diagnosis/ Management. 9th edition. 2010;1447-1476.
49. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323-1330. (Pubitemid 23333873)
50. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331-1336. (Pubitemid 23333874)
51. Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8:463-470.
52. Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931-939.
53. Lewis JH. Liver biopsy differentiates DILI from autoimmune hepatitis. Nature Rev Gastroenterol Hepatol. 2011;8:540-542.
54. Lewis JH, Kleiner D. Hepatic Injury due to Drugs, herbal compounds, chemicals and toxins. In: Burt AD, Portmann BC, Ferrell LD, eds. MacSween's Pathology of the Liver. 6th ed. Edinburgh: Churchill Livingstone Elsevier; 2012:645-760.
55. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: Promises and pitfalls. Clin Liver Dis. 2007; 11:477-505. (Pubitemid 47302343)
56. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117-2126.
57. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ. 1999;319:1541.
58. Björnsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010;32:3-13.
59. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology. 2001;33:308-310. (Pubitemid 32016915)
60. Nathwani RA, Kumar SR, Reynolds TB, et al. Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol. 2005;100:295-298. (Pubitemid 40314512)
61. Henrion J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore). 2003;82:392-406. (Pubitemid 37448566)
62. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in longterm clinical trials of ximelagatran. Drug Saf. 2005;28:351-370. (Pubitemid 40545769)
63. Lewis JH, Larrey D, Olsson R, et al. Utility of the Roussel Uclaf causality assessment method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran. Int J Clin Pharmacol Ther. 2008;46:327-339. (Pubitemid 352005926)
64. Friis RH, Sellers TA. Epidemiology for Public Health Practice. Sudbury, MA: Jones & Bartlett Learning 2009:93-140.
65. Berry DC, Knapp P, Raynor DK. Provision of information about drug side-effects to patients. Lancet. 2002;359:853-854. (Pubitemid 34233761)
66. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol. 2006;4:902-907. (Pubitemid 43994535)
67. Segarra-Newnham M, Parra D, Martin-Cooper EM. Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus. Pharmacotherapy. 2007;27:845-851. (Pubitemid 46849428)
68. Henderson LM, Patel S, Giordano TP, Green L, El-Serag HB. Statin therapy and serum transaminases among a cohort of HCV-infected veterans. Dig Dis Sci. 2010;55:190-195.
69. Madhoun MF, Bader T. Statins improve ALT values in chronic hepatitis C patients with abnormal values. Dig Dis Sci. 2010;55:870-871.
70. Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. 2010;52:864-874.
71. Gopal K, Johnson TC, Gopal S, et al. Correlation between betalipoprotein levels and outcome of hepatitis C treatment. Hepatology. 2006;44:335-340. (Pubitemid 44214872)
72. Molina S, Castet V, Fournier-Wirth C, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol. 2007; 46:411-419. (Pubitemid 46201721)
73. Amemiya F, Maekawa S, Itakura Y, et al. Tageting lipid metabolism in the treatment of hepatitis C virus infection. J Infect Dis. 2008;197:361-370. (Pubitemid 351263417)
74. Ikeda M, Abe K, Yamada M, et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006;44:117-125. (Pubitemid 44049145)
75. Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci. 2007;105:145-150. (Pubitemid 350106803)
76. Delang L, Paeshuvse J, Vliegen I, et al. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatolohy. 2009;50:6-16.
77. Mihaila R, Nedelcu L, Fratila O, et al. Lovastatin and fluvastatin reduce viremia and the pro-inflammatory cytokines in the patients with chronic hepatitis C. Hepatogastroenterology. 2009;56:1704-1709.
78. Milazzo L, Meroni L, Galazzi M, et al. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat. 2009;16:479-484.
79. Bader T, Fazili J, Madhoun M, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol. 2008;103: 1383-1389. (Pubitemid 351813920)
80. Rao GA, Pandva PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology. 2011;140:144-152.
81. Shimada M, Yoshida S, Masuzaki R, Schuppan D. Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study. J Hepatol. 2012;56:298-302.
82. Bader T, Korba B. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antiviral Res. 2010;86:241-245.
83. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990-994.
84. Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136: 1651-1658.
85. El-Serag HB, Johnson ML, Hachem C, et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136: 1601-1608.
86. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B infection. J Clin Oncol. 2012;30:623-630.
87. Zhang W, Wu J, Zhou L, Xie HY, Zheng SS. Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol. 2010;48:1167-1174.
88. Relja B, Meder F, Wilhelm K, Henrich D, Marzi I, Lehnert M. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010;26:735-741.
89. Relja B, Meder F, Wang M, et al. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. Int J Oncol. 2011;38:879-885.
90. Popovich DG, Tiaras F, Yeo CR, Zhang W. Lovastatin interacts with natural products to influence cultured hepatocarcinoma cell (hep-g2) growth. Am Coll Nutr. 2010;29:204-210.
91. Dold S, Laschke MW, Lavasani S, et al. Simvastatin protects against cholestasis-induced liver injury. Br J Pharmacol. 2009;156:466-474.
92. Demirbilek S, Tas E, Gurunluoglu K, et al. Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis. Ped Surg Int. 2007;23:155-162. (Pubitemid 46175220)
93. Russo L, Gracia-Sancho J, García-Calderó H, et al. Addition of simvastatin to cold storage prevents endothelial dysfunction in explanted rat livers. Hepatology. 2012;55:921-930.
94. Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA. 2001;286: 831-833. (Pubitemid 33015577)
95. Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring with statin use? Am J Cardiol. 2004;94:30F-34F. (Pubitemid 39425216)
96. Leaver H. Compliance to recommended liver function monitoring in patients on statin therapy. Cardiovasc Ther. 2009;27:96-100.
97. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97:89C-94C.
98. Ward S. A systemic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11:1-160.
99. MacCarthy EP. Important Drug Warning. Market withdrawal of Baycol (cervistatin). Bayer Corporation, West Haven, CT. August 8, 2001.
100. Omar MA, Wilson JP. FDA adverse event reports on statinassociated rhabdomyolysis. Ann Pharmacother. 2002;22: 441-457.
101. Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011;21:280-288.
102. Conforti A, Magro L, Moretti U, et al. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy. Drug Saf. 2006;29:1163-1172. (Pubitemid 44904831)
103. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in Swedish University Hospital Outpatient Hepatology Clinic. Aliment Pharmacol Ther. 2006;24:1187-1195. (Pubitemid 44427506)